This is the authors' abstract. We don't add key points for this paper.
Our results suggest that modulating CK-1δ activity could be considered a novel therapeutic approach for the treatment of FTLD-TDP and other TDP-43 proteinopathies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Alquézar et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: